Summary of United Therapeutics Conference Call on Phase III ADVANCE OUTCOMES Clinical Trial Results Company Overview - **Company**: United Therapeutics Corporation - **Ticker**: NasdaqGS: UTHR - **Event Date**: March 02, 2026 - **Focus**: Results of the Phase III ADVANCE OUTCOMES Clinical Trial for ralinepag, a treatment for pulmonary arterial hypertension (PAH) Key Points Clinical Trial Results - **Ralinepag Efficacy**: Ralinepag is over 3 times more likely to avoid disease progression events in PAH compared to standard double therapy (ETRA and PDE5 inhibitor) [4][5] - **Primary Endpoint Achievement**: The trial met its primary endpoint with a hazard ratio of 0.45, indicating a 55% reduction in the risk of clinical worsening events [20] - **Statistical Significance**: The results were statistically significant with a P value of less than 0.0001 [5] - **Secondary Endpoints**: The treated group showed a 47% higher likelihood of clinical improvement compared to background therapy [5] Patient Population and Study Design - **Demographics**: Predominantly female participants in their 50s, with an average time since diagnosis of about 4.5 years [15][18] - **Background Therapy**: 80% of participants were on dual background therapy, indicating a heavily pre-treated population [15] - **Functional Class**: Most participants were classified as functional class 2, with some in class 3 [18] Treatment Characteristics - **Dosing**: Ralinepag is a once-daily oral medication, which is expected to improve patient compliance compared to multiple daily doses of other therapies [4][39] - **Pharmacokinetics**: It has best-in-class pharmacokinetics with a long half-life and stable plasma concentrations, allowing for effective once-daily dosing [5] Safety Profile - **Adverse Events**: Common side effects included headache, diarrhea, nausea, and jaw pain, consistent with other prostacyclins. Discontinuation due to adverse events was reported at less than 10% in the active group [27][53] - **No New Safety Signals**: The safety profile was as expected, with no unexpected side effects reported [27][54] Market Implications - **Potential Market Expansion**: Ralinepag is expected to expand the oral prostacyclin market, potentially treating patients who previously could not justify oral prostacyclin therapy due to milder disease status [81] - **Prescriber Uptake**: The ease of use and significant efficacy results are anticipated to lead to high prescriber uptake, especially for new patients diagnosed with PAH [48][62] Future Directions - **Combination Therapies**: Discussions are ongoing regarding the potential for ralinepag to be used in combination with other therapies, including Winrevair [74] - **Regulatory Approval**: The company plans to seek FDA approval for ralinepag, with expectations for it to be used early in treatment regimens for PAH patients [62] Conclusion - **Transformative Impact**: The results from the ADVANCE OUTCOMES trial are seen as transformative for the treatment of PAH, with the potential to significantly improve patient outcomes and quality of life [6][8]